International Journal of Myeloma
Online ISSN : 2187-3143
Volume 6, Issue 3
Displaying 1-1 of 1 articles from this issue
ORIGINAL
  • Morio MATSUMOTO, Yuri MIYAZAWA, Hiroko KOYA, Yohei OSAKI, Atsushi ISOD ...
    Article type: ORIGINAL
    2016 Volume 6 Issue 3 Pages 13-16
    Published: 2016
    Released on J-STAGE: July 22, 2022
    JOURNAL FREE ACCESS

    The safety and efficacy of denosumab were retrospectively assessed in patients with multiple myeloma. This study included 25 patients treated with denosumab from May 2012 to March 2014. No skeletal-related events (SREs) due to multiple myeloma occurred. Urine N-telopeptide/creatinine decreased in all of 5 assessed patients 1 month after denosumab treatment, and urine deoxypyridinoline/creatinine decreased in 4 of 5 assessed patients. Osteonecrosis of the jaw was not observed. Hypocalcemia developed in 11 patients (44%). One patient with Grade 4 hypocalcemia complained of numbness of the extremities; however, the other patients had no complaint. On univariate analysis, the incidence of hypocalcemia was significantly higher in patients with than in those without renal insufficiency (p = 0.007) and patients with high than in those with low β-2-microglobulin (p = 0.017). On multivariate analysis, renal insufficiency was a risk factor for the development of hypocalcemia (p = 0.01). The patients who had prophylactic Ca and vitamin D3 supplementation had a significantly lower incidence of hypocalcemia than the others (p = 0.047). In conclusion, treatment with denosumab is safe and effective to prevent SREs in patients with multiple myeloma. Prophylaxis for hypocalcemia with calcium and/or vitamin D3 supplementation is necessary, especially in patients with renal insufficiency.

    Download PDF (250K)
feedback
Top